LENZ
LENZ clinical trials: LENZ Therapeutics, Inc.
Every trial on ClinicalTrials.gov where LENZ Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 8
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
LENZ on the catalyst calendar · LENZ registry changes
- Primary completion Dec 14, 2023ActualPhase 3NCT05728944Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of PresbyopiaLENZ Therapeutics, Inc · PresbyopiaCompletedLENZLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 9, 2024ActualPhase 3NCT05753189Phase 3 Safety Study of LNZ100 and LNZ101 for the Treatment of Presbyopia SubjectsLENZ Therapeutics, Inc · PresbyopiaCompletedLENZLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2023ActualPhase 3NCT05656027Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of PresbyopiaLENZ Therapeutics, Inc · PresbyopiaCompletedLENZLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 14, 2022ActualPhase 2NCT05431543Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of PresbyopiaLENZ Therapeutics, Inc · PresbyopiaCompletedLENZLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 22, 2022ActualPhase 2NCT05294328Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of PresbyopiaLENZ Therapeutics, Inc · PresbyopiaCompletedLENZLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 3, 2023ActualPhase 1NCT05936489Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With PresbyopiaLENZ Therapeutics, Inc · Eye DiseasesCompletedLENZLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 20, 2018ActualPhase 2NCT03201562A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate PresbyopiaLENZ Therapeutics, Inc · PresbyopiaCompletedLENZLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2015ActualPhase 2NCT02554396Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate PresbyopiaLENZ Therapeutics, Inc · PresbyopiaCompletedLENZLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 19, 2024ActualPhase 3NCT06045299Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the PresbyopiaCorxel Pharmaceuticals · PresbyopiaCompletedLENZCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 10, 2024ActualPhase 1NCT06270030Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With PresbyopiaCorxel Pharmaceuticals · PresbyopiaCompletedLENZCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner